115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of nivolumab, ipilimumab plus bicalutamide in metastatic breast cancer
    Meeting Abstract

    Page, D. B.; Kaur, L.; Hong, E. C. C.; Su, A.; Moxon, N.; Mellinger, S.; Kelly, T.; Kelley, A.; Fredrich, N.; Seino, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II dose escalation study evaluating first-in-class eIF4A inhibitor zotatifin in ER plus metastatic breast cancer
    Meeting Abstract

    Rosen, E.; Caswell-Jin, J.; Berz, D.; Mai, N.; Fulgar, G.; Densel, M.; Chiang, G.; Sperry, S.; Warner, D.; Meric-Bernstam, F.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity
    Meeting Abstract

    Thorball, C. W.; Quandt, Z.; Saha, A.; Yao, L.; Midda, P.; Xu, Y.; Bejan, C. A.; Hodel, F.; Stravodimou, A.; Shearer-Kang, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Development and validation of a 19-feature classifier that predicts response to neoadjuvant trastuzumab emtansine (T-DM1) in breast cancer patients
    Meeting Abstract

    Pareja, F.; Paul, E. D.; Huraiová, B.; Valková, N.; Matyasovská, N.; Gábrisová, D.; Gubová, S.; Ignacáková, H.; Ondris, T.; Bendíková, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis
    Meeting Abstract

    Tarantino, P.; Rugo, H. S.; Curigliano, G.; O'Shaughnessy, J.; Janni, W.; Jhaveri, K.; Mouabbi, J. A.; Brufsky, A. M.; Hamilton, E. P.; Oregan, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers
    Meeting Abstract

    Sacco, J. J.; Carvajal, R. D.; Hamid, O.; Kirk, P. B.; Collins, L.; Butler, M. O.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A. P.; Hernandez-Aya, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • The role of CTNNA1 truncating variants in hereditary diffuse gastric cancer (HDGC)
    Meeting Abstract

    Lobo, S.; Dias, A.; Ferreira, M.; Herrera-Mullar, J.; Svrcek, M.; Hueneburg, R.; Moreira, L.; Tinschert, S.; Boussemart, L.; Balmaña, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • HERIZON-BTC-302: A phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)
    Meeting Abstract

    Macarulla Mercade, T.; Harding, J. J.; Pant, S.; Wu, X.; Garfin, P.; Okusaka, T.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial
    Meeting Abstract

    Senan, S.; Spigel, D. R.; Cho, B. C.; Laktionov, K.; Zenke, Y.; Lee, K. H.; Wang, Q.; Navarro Mendivil, A. F.; Buchmeier, E. L.; Sezgin Goksu, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)
    Meeting Abstract

    Powles, T. B.; van der Heijden, M. S.; Galsky, M. D.; Al-Ahmadie, H.; Meeks, J. J.; Nishiyama, H.; Vu, T. Q.; Antonuzzo, L.; Wiechno, P.; Atduev, V.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save